CD28 and angioimmunoblastic T-cell lymphoma: CTLA4-CD28 gene fusions have been preferably observed in AITL, PTCL-NOS, ATLL, and cutaneous T-Cell lymphomas and, therefore, may represent a potential target for anti-CTLA4 immunotherapy.